Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NMBR | P28336 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468161 | 0.89 | SIRT2 (0.55) | MDM4TP53NMBRSIRT2MDM2 | |
| SCHEMBL13227674 | 0.89 | MDM4 (0.54) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL30433831 | 0.89 | MDM4 (0.54) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL12994493 | 0.89 | MDM4 (0.54) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL1737899 | 0.89 | MDM4 (0.54) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL29368020 | 0.89 | MDM4 (0.54) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL29399601 | 0.88 | SIRT2 (0.49) | MDM4TP53NMBRSIRT2 | |
| SCHEMBL28913050 | 0.88 | SIRT2 (0.49) | MDM4TP53NMBRSIRT2 | |
| SCHEMBL28913051 | 0.88 | SIRT2 (0.49) | MDM4TP53NMBRSIRT2 | |
| SCHEMBL29427171 | 0.88 | NMBR (0.48) | MDM4TP53NMBRSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137001-A | Polypeptide compound and application thereof | 成都普康唯新生物科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024159569-A1 | METHOD FOR SYNTHESIZING SEMAGLUTIDE | 浙江九洲药业股份有限公司 | 2024-08-08 | — | — | WO | disclosed |
| US-20230133716-A1 | PREPARATION METHOD FOR SEMAGLUTIDE | Shenzhen JYMed Technology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133716-A1 | PREPARATION METHOD FOR SEMAGLUTIDE | GCG, GLP1R, DPP7 | MDM4 3641/4885TP53 2867/4885NMBR 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.